WEED Share Price Performance
CA$1.43
-1.25 (-46.64%)
n/aintrinsic discount
Price CA$1.43
AnalystLowTarget
AnalystConsensusTarget CA$3.20
AnalystHighTarget CA$5.00
Share Pricen/a
Canopy Growth Corporation Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 54 Fair Values set on narratives written by author
WEED Community Narratives
AN
Fair Value CA$0 n/aintrinsic discount
Poland Restrictions And Rising Costs Will Constrain Global Expansion
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value CA$3.2 55.3% undervalued intrinsic discount
European Expansion And Operational Improvements Will Unlock Cannabis Potential
0users have liked this narrative
1users have commented on this narrative
40users have followed this narrative
AN
Fair Value CA$5 71.4% undervalued intrinsic discount
Global Cannabis Legalization Will Unlock Medical And Wellness Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Global Cannabis Legalization Will Unlock Medical And Wellness Markets
Key Takeaways Regulatory reforms and global legalization trends are unlocking major new markets, supporting aggressive expansion and elevating Canopy's market share and margin potential. Innovation in high-value products and improved capital access are enabling Canopy to dominate premium segments, fueling higher long-term profitability and growth.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
CA$5
71.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
14.73% p.a.
Profit Margin
4.78%
Future PE
137.82x
Price in 2029
CA$3.34
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Key Takeaways Expanding internationally and innovating with premium and alternative products are expected to drive sustainable revenue growth and strengthen brand equity across key markets. Cost-cutting measures and operational improvements aim to enhance margins and position the company for success, particularly if U.S. federal legalization advances.Read more
359
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
40users have followed this narrative
AN
CA$3.2
55.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
4% p.a.
Profit Margin
4.78%
Future PE
106.9x
Price in 2029
CA$2.13
Poland Restrictions And Rising Costs Will Constrain Global Expansion
Key Takeaways Ongoing regulatory challenges, high costs, and operational inefficiencies are constraining revenue growth and preventing sustainable profitability for Canopy Growth. Market oversupply, price compression, and necessary shareholder dilution are further weakening margins and eroding long-term shareholder value.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CA$0
n/aintrinsic discount
AnalystLowTarget's Fair Value
Revenue
8.07% p.a.
Profit Margin
1.2%
Future PE
N/A
Price in 2028
CA$0
Trending Discussion
Recently Updated Narratives
AN
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Fair Value: CA$5 71.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Fair Value: CA$3.2 55.3% undervalued intrinsic discount
40 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Poland Restrictions And Rising Costs Will Constrain Global Expansion
Fair Value: CA$0 0% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Canopy Growth Corporation Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.87
- 26.56%
- -117.57%
- 29.7%
About WEED
- Founded
- n/a
- Employees
- 960
- CEO
- WebsiteView website
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
